Matsuoka Fuminori, Kiriu Tatsunori, Kaisho Saki, Nishii Masahiko, Dokuni Ryota, Mizuguchi Takao, Kashima Yukio, Kotani Yoshikazu
Department of Respiratory Medicine, Hyogo Prefectural Awaji Medical Center, Japan.
Department of Hematology, Hyogo Prefectural Awaji Medical Center, Japan.
Intern Med. 2025 Jun 1;64(11):1737-1741. doi: 10.2169/internalmedicine.3859-24. Epub 2024 Nov 1.
Primary tracheal diffuse large B-cell lymphoma (DLBCL) is a rare, aggressive, but potentially curable malignancy that is difficult to diagnose and treat. We herein report a 93-year-old Japanese man diagnosed with primary tracheal DLBCL after presenting with progressive dyspnea due to severe upper tracheal stenosis during follow-up for pulmonary amyloidosis. Following the diagnosis, the patient was treated with corticosteroids, followed by R-CHOP chemotherapy, resulting in a therapeutic response. The patient's history of pulmonary amyloidosis may have contributed to the development of tracheal DLBCL. An evaluation of the risks and benefits of various therapeutic interventions is crucial for providing optimal patient-specific care.
原发性气管弥漫性大B细胞淋巴瘤（DLBCL）是一种罕见、侵袭性强但有可能治愈的恶性肿瘤，诊断和治疗都很困难。我们在此报告一名93岁的日本男性，他在因肺淀粉样变性接受随访期间，因严重的上气管狭窄出现进行性呼吸困难后，被诊断为原发性气管DLBCL。确诊后，患者接受了糖皮质激素治疗，随后进行了R-CHOP化疗，取得了治疗反应。患者的肺淀粉样变性病史可能促成了气管DLBCL的发生。评估各种治疗干预措施的风险和益处对于提供最佳的个体化患者护理至关重要。
